Neoantigen-based peptide vaccine

Phase 2Vaccine

TThe First Affiliated Hospital of Nanchang University

Neoantigen-based peptide vaccine is one of 73 small molecule programs targeting First-line Treatment. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

First-Line TreatmentRecruiting

Advanced Malignant Solid TumorsRecruiting

Second-Line TreatmentRecruiting

First-Line TreatmentPreclinical

Recruiting

Advanced Malignant Solid TumorsPreclinical

Recruiting

Second-Line TreatmentPhase 2

Recruiting

Competition

Competitive Landscape

74 competitors in First-Line Treatment

#DrugCompanyPhaseTrials

Gemzar

Johnson & Johnson

Phase 3

4 2

Lexapro

AbbVie

Phase 3

1 3

Tuoyi

SSun Yat-sen University

Phase 3

6 4

Vepesid

AAvyxa

Phase 3

3 5

Adstiladrin

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Phase 3

2 6

Tyvyt

Innovent Biologics (Suzhou) Co. Ltd.

Phase 3

2 7

Zoloft

VViatris Specialty LLC

Phase 3

1 8

Seroquel

EEngelhard Arzneimittel GmbH & Co.KG

Phase 3

1 9

Wellbutrin

GGlaxo Dba Glaxosmithkline

Phase 3

1 10

Effexor

WWyeth-Lederle Vaccines

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

N/ARecruiting

First-Line Treatment

NCT06752044

N/ARecruiting

First-Line Treatment

NCT06751914

N/ARecruiting

Second-Line Treatment

NCT06751966

Clinical

Trials by Indication[1]

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Neoantigen-based peptide vaccine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Neoantigen-based peptide vaccine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Neoantigen-based peptide vaccine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — The First Affiliated Hospital of Nanchang University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Vaccine[2]
Highest Phase: Phase 2[1]
Company: TThe First Affiliated Hospital of Nanchang University

Neoantigen-based peptide vaccine

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

First-line Treatment2 trials

Second-line Treatment2 trials

Advanced Malignant Solid Tumors1 trial

References

Drug Info

Quick Facts

Related News